Christof V.
- Country
- Belgium
- Department
- oncology
Research Overview
- Phase 1 Open-Label Dose Escalation and Expansion Study of SNV1521 in Patients with Advanced Solid Tumors
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- A Phase 3 Study of JNJ-78278343 and Docetaxel Versus Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 431 of 700 partner sites.
Specializations
Urological Oncology
Primary focus on developing treatments for bladder cancer and urothelial carcinoma, with particular emphasis on novel therapeutic approaches for both muscle-invasive and non-muscle invasive disease states.
- Advanced Urothelial Cancer Treatment
- HER2-Expressing Tumors
- Bladder Cancer Immunotherapy
Extensive work in evaluating combination therapies involving immunotherapy and targeted treatments for various stages of bladder cancer.
Prostate Cancer Research
Specialized investigation of metastatic prostate cancer treatments, including both castration-sensitive and castration-resistant disease states.
- Biomarker-Driven Therapies
- Novel Hormonal Treatments
- Advanced Disease Management
Focus on developing personalized treatment approaches using biomarker signatures and innovative therapeutic combinations.
Gynecologic Oncology
Research expertise in treating ovarian cancer and endometrial carcinoma, with particular attention to advanced and recurrent disease states.
- Neoadjuvant Therapy Approaches
- Maintenance Treatment Strategies
- Combination Immunotherapy
Investigation of novel therapeutic combinations and targeted approaches for gynecologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.